NewsRx Logo Login/Signup
Home Newsletters Products Library About Us Contact -- Search NewsRx

NewsRx | Free Trials
Advertisement
VerticalNews | Global Warming
Advertisement
NewsRx | Free Trials
Advertisement
----------
------------
NewsRx on Facebook
-----
Press Release Submissions
PR Login
*
*

Medical Devices & Surgical Technology Week

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Medical Devices & Surgical Technology Week

Learn More

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Buy Now



Chronic Lymphocytic Leukemia



‘Modular’ Leukemia Drug Shows Promise in Early Testing



July 22nd, 2007

A new type of engineered drug candidate has shown promise in treating chronic lymphocytic leukemia in both test tube and early animal tests, a new study shows.

The agent represents a new class of agents called small modular immunopharmaceuticals. Called CD37-SMIP, the agent targets a protein called CD37 on the surface of these leukemia cells.

The study shows that the agent can successfully attach to the protein on the leukemia cells and kill them. The agent works both by triggering the cells’ self-destruction and by causing a particular class of immune cells to attack them.

In an animal model, the agent worked equally as well as...


Source: Medical Devices & Surgical Technology Week (2007-07-22)

NewsRx Passes
Advertisement
More Articles

Related Topics

------------------------
Security by Verisign PR Login